| Pharmaceutical risk-sharing agreements JP Cook, JA Vernon, R Manning Pharmacoeconomics 26, 551-556, 2008 | 110 | 2008 |
| Changing rules in tort law and the market for childhood vaccines RL Manning The Journal of Law and Economics 37 (1), 247-275, 1994 | 106 | 1994 |
| Products liability and prescription drug prices in Canada and the United States RL Manning The Journal of Law and Economics 40 (1), 203-244, 1997 | 94 | 1997 |
| The benefits of switching smoking cessation drugs to over‐the‐counter status TE Keeler, T Hu, A Keith, R Manning, MD Marciniak, M Ong, HY Sung Health Economics 11 (5), 389-402, 2002 | 58 | 2002 |
| Have changing liability rules compensated workers twice for occupational hazards? Earnings premiums and cancer risks JR Lott, Jr, RL Manning The Journal of Legal Studies 29 (1), 99-130, 2000 | 43 | 2000 |
| Vaccination and GDP growth rates: Exploring the links in a conditional convergence framework NA Masia, J Smerling, T Kapfidze, R Manning, M Showalter World Development 103, 88-99, 2018 | 32 | 2018 |
| The economics of direct-to-consumer advertising of prescription drugs R Manning, A Keith Economic Realities in Health Care Policy 2 (1), 10-15, 2001 | 30 | 2001 |
| How term limits enhance the expression of democratic preferences E Elhauge, JR Lott Jr, RL Manning Supreme Court Economic Review 5, 59-80, 1997 | 27 | 1997 |
| Information technology in the insurance industry: A forecast of utilization and impact RL Manning, MK Stephenson, JD Todd Journal of Risk and Insurance, 711-722, 1985 | 21 | 1985 |
| Logit regressions with continuous dependent variables measured with error RL Manning Applied Economics Letters 3 (3), 183-184, 1996 | 19 | 1996 |
| An economic analysis of global policy proposals to prohibit compensation of blood plasma donors HG Grabowski, RL Manning International Journal of the Economics of Business 23 (2), 149-166, 2016 | 15 | 2016 |
| Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products MW Skinner, PA Hedlund Hoppe, HG Grabowski, R Manning, ... Transfusion 56 (811), 2889-2894, 2016 | 12 | 2016 |
| Is the insurance aspect of producer liability valued by consumers? Liability changes and childhood vaccine consumption RL Manning Journal of Risk and Uncertainty 13, 37-51, 1996 | 12 | 1996 |
| Brand-name versus generic drugs R Manning, R Smith Health Affairs 30 (10), 2027, 2011 | 6 | 2011 |
| Similar products at different prices: can biopharmaceutical companies segment markets? R Manning, C Stomberg, B Scher, K Twigg, A Huson International Journal of the Economics of Business 22 (2), 231-243, 2015 | 5 | 2015 |
| Economic impact of product liability in US prescription drug markets R Manning Int'l Bus. Law. 29, 104, 2001 | 2 | 2001 |
| Prices and Related Controversies in the Biopharmaceutical Industry RL Manning International Journal of the Economics of Business 25 (1), 157-166, 2018 | 1 | 2018 |
| Drug Prices and Medical Innovation: A Response to Yu, Helms, and Bach H Grabowski, R Manning Health Affairs Forefront, 2017 | 1 | 2017 |
| Have Changing Liability Rules Compensated Workers Twice for Occupational Hazards?: Earnings Premiums and Cancer Risks JR Lott Jr, RL Manning Working paper, 1995 | 1 | 1995 |
| Reply to Comment on “Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US” WV Padula, S Parasrampuria, MP Socal, RM Conti, GF Anderson PharmacoEconomics 38, 1375-1376, 2020 | | 2020 |
